User login
Officials at the Centers for Disease Control and Prevention are asking U.S. hospitals to enroll in a new national surveillance system for monitoring adverse events in patients receiving blood transfusions.
The voluntary Hemovigilance Module is the latest addition to the CDC's National Healthcare Safety Network, which allows health care providers to securely submit data on heath care–associated infections via the Internet. Through the network, the CDC provides hospitals with risk-adjusted data to be used for internal comparisons and local quality-improvement activities.
“Health care facilities that join the Hemovigilance Module will now have a yardstick by which to measure their current safety initiatives and their future efforts,” Dr. Dan Pollock, chief of the branch that leads the CDC safety network, said in a statement. “Through this system, health care facilities can also see how their performance stacks up to similar facilities nationwide, with a goal of designing the best processes to protect patients' health and reduce health care costs.”
Previously, hospitals have been left to monitor transfusion-related adverse events on their own, according to the CDC. Hospitals that opt into the new system can submit data confidentially; the CDC, along with some private partners, will use the national data to identify potential strategies to improve transfusion safety.
The CDC is offering the module, training, and user support free of charge.
The module was developed by the CDC and the AABB, an international association representing organizations involved in transfusion and cellular therapies.
The AABB called the launch of the surveillance system an important step forward. “The U.S. is the only developed country that does not have an established method to track and monitor adverse events associated with blood transfusion on a national level,” AABB's CEO Karen Shoos Lipton said in a statement.
More information on the Hemovigilance Module is available online at www.cdc.gov/nhsn/bio.html
Officials at the Centers for Disease Control and Prevention are asking U.S. hospitals to enroll in a new national surveillance system for monitoring adverse events in patients receiving blood transfusions.
The voluntary Hemovigilance Module is the latest addition to the CDC's National Healthcare Safety Network, which allows health care providers to securely submit data on heath care–associated infections via the Internet. Through the network, the CDC provides hospitals with risk-adjusted data to be used for internal comparisons and local quality-improvement activities.
“Health care facilities that join the Hemovigilance Module will now have a yardstick by which to measure their current safety initiatives and their future efforts,” Dr. Dan Pollock, chief of the branch that leads the CDC safety network, said in a statement. “Through this system, health care facilities can also see how their performance stacks up to similar facilities nationwide, with a goal of designing the best processes to protect patients' health and reduce health care costs.”
Previously, hospitals have been left to monitor transfusion-related adverse events on their own, according to the CDC. Hospitals that opt into the new system can submit data confidentially; the CDC, along with some private partners, will use the national data to identify potential strategies to improve transfusion safety.
The CDC is offering the module, training, and user support free of charge.
The module was developed by the CDC and the AABB, an international association representing organizations involved in transfusion and cellular therapies.
The AABB called the launch of the surveillance system an important step forward. “The U.S. is the only developed country that does not have an established method to track and monitor adverse events associated with blood transfusion on a national level,” AABB's CEO Karen Shoos Lipton said in a statement.
More information on the Hemovigilance Module is available online at www.cdc.gov/nhsn/bio.html
Officials at the Centers for Disease Control and Prevention are asking U.S. hospitals to enroll in a new national surveillance system for monitoring adverse events in patients receiving blood transfusions.
The voluntary Hemovigilance Module is the latest addition to the CDC's National Healthcare Safety Network, which allows health care providers to securely submit data on heath care–associated infections via the Internet. Through the network, the CDC provides hospitals with risk-adjusted data to be used for internal comparisons and local quality-improvement activities.
“Health care facilities that join the Hemovigilance Module will now have a yardstick by which to measure their current safety initiatives and their future efforts,” Dr. Dan Pollock, chief of the branch that leads the CDC safety network, said in a statement. “Through this system, health care facilities can also see how their performance stacks up to similar facilities nationwide, with a goal of designing the best processes to protect patients' health and reduce health care costs.”
Previously, hospitals have been left to monitor transfusion-related adverse events on their own, according to the CDC. Hospitals that opt into the new system can submit data confidentially; the CDC, along with some private partners, will use the national data to identify potential strategies to improve transfusion safety.
The CDC is offering the module, training, and user support free of charge.
The module was developed by the CDC and the AABB, an international association representing organizations involved in transfusion and cellular therapies.
The AABB called the launch of the surveillance system an important step forward. “The U.S. is the only developed country that does not have an established method to track and monitor adverse events associated with blood transfusion on a national level,” AABB's CEO Karen Shoos Lipton said in a statement.
More information on the Hemovigilance Module is available online at www.cdc.gov/nhsn/bio.html